|
1.
|
|
10 p, 476.1 KB |
Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors
/
Le Tourneau, C. (Paris-Saclay University) ;
Becker, H. (University of Freiburg) ;
Claus, R. (Medical Faculty Augsburg University) ;
Elez, Elena (Vall d'Hebron Institut d'Oncologia) ;
Ricci, F. (Paris-Saclay University) ;
Fritsch, R. (University of Freiburg) ;
Silber, Y. (Medical Faculty Augsburg University) ;
Hennequin, A. (Centre Georges-François Leclerc) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Jayadeva, G. (Boehringer Ingelheim International GmbH) ;
Luedtke, D. (Boehringer Ingelheim Pharma GmbH and Co KG) ;
He, M. (Boehringer Ingelheim Pharmaceuticals Inc.) ;
Isambert, N. (Centre Georges-François Leclerc) ;
Universitat Autònoma de Barcelona
BI 836880 is a humanized bispecific nanobody® that inhibits vascular endothelial growth factor and angiopoietin-2. Here, we report results from two phase I, nonrandomized, dose-escalation studies (NCT02674152 and NCT02689505; funded by Boehringer Ingelheim) evaluating BI 836880 in patients with confirmed locally advanced or metastatic solid tumors, refractory to standard therapy, or for which standard therapy was ineffective. [...]
2022 -  10.1016/j.esmoop.2022.100576
ESMO open, Vol. 7 (september 2022)
|
|
|
2.
|
|
10 p, 598.8 KB |
Liver transplantation in metastatic colorectal cancer : are we ready for it?
/
Ros Montañá, Javier (Vall d'Hebron Institut d'Oncologia) ;
Salva, Francesc (Vall d'Hebron Institut d'Oncologia) ;
Dopazo, Cristina (Hospital Universitari Vall d'Hebron) ;
López, Daniel (Vall d'Hebron Institut d'Oncologia) ;
Saoudi, Nadia (Vall d'Hebron Institut d'Oncologia) ;
Baraibar, Iosune (Vall d'Hebron Institut d'Oncologia) ;
Charco, Ramon (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Elez, Elena (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
Colorectal cancer (CRC) is a prevalent disease worldwide, with more than 50% of patients developing metastases to the liver. Five-year overall survival remains modest among patients with metastatic CRC (mCRC) treated with conventional therapies however, liver transplantation in a highly selected population can improve clinical outcomes with an impressive 5-year overall survival of 83%. [...]
2023 - 10.1038/s41416-023-02213-1
British Journal of Cancer, Vol. 128 (march 2023) , p. 1797-1806
|
|
|
3.
|
|
14 p, 3.3 MB |
A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study
/
Español-Rego, Marta (Hospital Clínic i Provincial de Barcelona) ;
Fernández-Martos, Carlos (Instituto Valenciano de Oncología. Medical Oncology Department) ;
Elez, Elena (Vall d'Hebron Institut d'Oncologia) ;
Foguet, Carles (Universitat de Barcelona. Department of Biochemistry and Molecular Medicine) ;
Pedrosa, Leire (Hospital Clínic i Provincial de Barcelona) ;
Rodríguez, Nuria (Centro de Investigación Biomédica en Red de Cáncer) ;
Ruiz-Casado, Ana (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Pineda, Estela (Hospital Clínic i Provincial de Barcelona) ;
Cid, Joan (Hospital Clínic i Provincial de Barcelona) ;
Cabezón, Raquel (Hospital Clínic i Provincial de Barcelona) ;
Oliveres, Helena (Hospital Clínic i Provincial de Barcelona) ;
Lozano, Miquel (Hospital Clínic i Provincial de Barcelona) ;
Ginés, Angels (Instituto Nacional de La Salud Carlos III. Networked Center for Hepatic and Digestive Diseases) ;
García-Criado, Angeles (Hospital Clínic i Provincial de Barcelona) ;
Ayuso, Juan Ramon (Hospital Clínic i Provincial de Barcelona) ;
Pagés, Mario (Hospital Clínic i Provincial de Barcelona) ;
Cuatrecasas, Miriam (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ;
Torres Benítez, Ferran (Universitat Autònoma de Barcelona. Unitat de Bioestadística) ;
Thomson, Timothy (Universidad Peruana Cayetano Heredia) ;
Cascante, Marta (Instituto Nacional de La Salud Carlos III) ;
Benítez Ribas, Daniel (Hospital Clínic i Provincial de Barcelona) ;
Torres Benítez, Ferran (Instituto Nacional de La Salud Carlos III)
Immune check-point blockade (ICB) has shown clinical benefit in mismatch repair-deficient/microsatellite instability high metastatic colorectal cancer (mCRC) but not in mismatch repair-proficient/microsatellite stable patients. [...]
2022 - 10.1007/s00262-022-03283-5
Cancer Immunology, Immunotherapy, Vol. 72 (september 2022) , p. 827-840
|
|
|
4.
|
|
11 p, 458.4 KB |
Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer
/
Yoshino, Takayuki (National Cancer Center Hospital East) ;
André, Thierry (Sorbonne University) ;
Kim, Tae Won (University of Ulsan) ;
Yong, Wei Peng (National University Cancer Institute) ;
Shiu, Kai-Keen (University College Hospital) ;
Jensen, Benny Vittrup (Herlev and Gentofte Hospital) ;
Jensen, Lars Henrik (University Hospital of Southern Denmark) ;
Punt, Cornelis J. A. (University Medical Center Utrecht) ;
Smith, Denis (Hôpital Haut-Lévêque) ;
García-Carbonero, Rocío (Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12)) ;
Alcaide-Garcia, Julia (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Gibbs, Peter (Western Hospital) ;
de la Fouchardiere, Christelle (Centre Léon Bérard) ;
Rivera, Fernando (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Elez, Elena (Vall d'Hebron Institut d'Oncologia) ;
Le, Dung T. (Johns Hopkins Medicine) ;
Adachi, Noriaki (Merck (Estats Units d'Amèrica)) ;
Fogelman, David (Merck(Estats Units d'Amèrica)) ;
Marinello, Patricia (Merck (Estats Units d'Amèrica)) ;
Diaz, Luis A. (Memorial Sloan Kettering Cancer Center) ;
Universitat Autònoma de Barcelona
The phase 3 KEYNOTE-177 study evaluated pembrolizumab versus chemotherapy with or without bevacizumab or cetuximab in patients with newly diagnosed, microsatellite-instability-high (MSI-H)/mismatch-repair-deficient (dMMR) metastatic colorectal cancer (mCRC). [...]
2022 - 10.1111/cas.15650
Cancer Science, Vol. 114 (december 2022) , p. 1026-1036
|
|
|
5.
|
|
9 p, 402.4 KB |
Gender influence on work satisfaction and leadership for medical oncologists : a survey of the Spanish Society of Medical Oncology (SEOM)
/
Elez, Elena (Vall d'Hebron Institut d'Oncologia) ;
Ayala de la Peña, Francisco (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ;
García Campelo, Rosario G. (Complexo Hospitalario Universitario) ;
García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ;
García Donas, J (Centro Integral Oncológico Clara Campal (CIOCC)) ;
González-del-Alba, Aránzazu (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
González-Flores, Encarnación (Hospital Universitario Virgen de las Nieves (Granada)) ;
Hidalgo, Julia (Hospital Lluis Alcanyís de Xativa) ;
Isla, Dolores (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Rodríguez-Lescure, Álvaro (Hospital General Universitario de Elche) ;
Safont, María José (Consorcio Hospital General Universitario Valencia) ;
Santaballa, Ana (Hospital Universitari i Politècnic La Fe (València)) ;
Villacampa Javierre, Guillermo (Vall d'Hebron Institut d'Oncologia) ;
Vera, Ruth (Complejo Hospitalario de Navarra) ;
Garrido, Pilar (Hospital Universitario Ramón y Cajal (Madrid))
Background: Women represent an increasing proportion of the oncology workforce; however, globally this does not translate into leadership roles, reflecting disparities in career opportunities between men and women. [...]
2021 - 10.1016/j.esmoop.2021.100048
ESMO open, Vol. 6 Núm. 2 (april 2021) , p. 100048
|
|
|
6.
|
|
8 p, 387.2 KB |
Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era : a study of the Spanish Society of Medical Oncology (SEOM)
/
Jiménez-Labaig, P. (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Pacheco-Barcia, Vilma (Hospital Central de la Defensa Gomez Ulla) ;
Cebrià, Annabel (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Gálvez, F. (Hospital Universitario de Jaén) ;
Obispo, B. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Páez, David (Institut d'Investigació Biomèdica Sant Pau) ;
Quílez, A. (Hospital Can Misses. Área de salud de Ibiza y Formentera (ASEF)) ;
Quintanar, T. (Hospital General Universitario de Elche) ;
Ramchandani, A. (Complejo Hospitalario Universitario Insular Materno Infantil) ;
Remon, Jordi (Hospital HM Delfos) ;
Rogado, J. (Hospital Universitario Infanta Leonor) ;
Sánchez, D.A. (Hospital Universitario Virgen de la Arrixaca (Múrcia)) ;
Sánchez-Cánovas, M. (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Sanz-García, E. (HM Sanchinarro Hospital-Centro Integral Oncológico Clara Campal (CIOOC)) ;
Sesma, A. (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Tarazona, N. (Centro de Investigación Biomédica en Red de Cáncer) ;
Cotés, A. (Hospital General de Elda) ;
González, E. (Hospital Universitario Virgen de las Nieves (Granada)) ;
Bosch-Barrera, J. (Hospital Universitari de Girona Doctor Josep Trueta) ;
Fernández Montes, Ana (Complejo Hospitalario Universitario de Ourense) ;
Felip, Enriqueta (Vall d'Hebron Institut d'Oncologia) ;
Vera, R. (Clínica Universidad de Navarra) ;
Rodríguez-Lescure, None (Hospital General Universitario de Elche) ;
Elez, Elena (Vall d'Hebron Institut d'Oncologia)
Background: Young oncologists are at particular risk of professional burnout, and this could have a significant impact on their health and care of their patients. The coronavirus disease 2019 (COVID-19) pandemic has forced rapid changes in professionals' jobs and training, with the consequent physical and psychological effects. [...]
2021 - 10.1016/j.esmoop.2021.100215
ESMO open, Vol. 6 Núm. 4 (august 2021) , p. 100215
|
|
|
7.
|
|
7 p, 716.5 KB |
Current professional standing of young medical oncologists in Spain : a nationwide survey by the Spanish Society of Medical Oncology + MIR section
/
Martinez, Domingo Antonio Sanchez (Instituto Murciano de Investigación Biosanitaria) ;
Quilez-Cutillas, Aliica (Department of Medical Oncology, Can Misses Hospital, Área de Salud de Ibiza y Formentera (ASEF), Ibiza, Illes Balears Spain) ;
Jimenez-Labaig, Pablo (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Sesma, Andrea (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Tarazona, Noelia (Centro de Investigación Biomédica en Red de Cáncer) ;
Pacheco-Barcia, Vilma (Torrejón University Hospital. Department of Medical Oncology) ;
Obispo, Berta (Hospital Universitario Infanta Leonor) ;
Páez, David (Institut d'Investigació Biomèdica Sant Pau) ;
Quintanar, Teresa (Hospital General Universitario de Elche) ;
Sanchez-Canovas, Manuel (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Fernández Montes, Ana (University Hospital Complex of Ourense (CHUO). Department of Medical Oncology) ;
Felip, Enriqueta (Vall d'Hebron Institut d'Oncologia) ;
Rodriguez-Lescure, Alvaro (Elche University General Hospital. Department of Medical Oncology) ;
Elez, Elena (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
There is a lack of knowledge about the career paths and employment situation of young medical oncologists. The aim of our study was to evaluate the current professional standing of these professionals in Spain. [...]
2022 - 10.1007/s12094-022-02989-3
Clinical & Translational Oncology, november 2022, p. 1-7
|
|
|
8.
|
|
13 p, 1.6 MB |
Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers
/
Fucà, Giovanni (Fondazione IRCCS Istituto Nazionale dei Tumori) ;
Cohen, Romain (Hôpital Saint-Antoine) ;
Lonardi, Sara (Istituto Oncologico Veneto IOV-IRCSS) ;
Shitara, Kohei (National Cancer Center Hospital East) ;
Elez, Elena (Vall d'Hebron Institut d'Oncologia) ;
Fakih, Marwan (City of Hope Comprehensive Cancer Center) ;
Chao, Joseph (City of Hope Comprehensive Cancer Center) ;
Klempner, Samuel J. (Harvard Medical School) ;
Emmett, Matthew (Harvard Medical School) ;
Jayachandran, Priya (University of Southern California) ;
Bergamo, Francesca (Istituto Oncologico Veneto IOV-IRCSS) ;
García, Marc Díez (Vall d'Hebron Institut d'Oncologia) ;
Mazzoli, Giacomo (Fondazione IRCCS Istituto Nazionale dei Tumori) ;
Provenzano, Leonardo (Fondazione IRCCS Istituto Nazionale dei Tumori) ;
Colle, Raphael (Hôpital Saint-Antoine) ;
Svrcek, Magali (Hôpital Saint-Antoine, AP-HP, and INSERM, Unité Mixte de Recherche Scientifique 938, Centre de Recherche Saint-Antoine, Equipe Instabilité des Microsatellites et Cancer, Equipe labellisée par la Ligue Nationale contre le Cancer) ;
Ambrosini, Margherita (Fondazione IRCCS Istituto Nazionale dei Tumori) ;
Randon, Giovanni (Fondazione IRCCS Istituto Nazionale dei Tumori) ;
Shah, Aakash Tushar (Baylor College of Medicine) ;
Salati, Massimiliano (University Hospital of Modena) ;
Fenocchio, Elisabetta (Candiolo Cancer Institute FPO-IRCCS) ;
Salvatore, Lisa (Fondazione Policlinico Universitario Agostino Gemelli IRCCS) ;
Chida, Keigo (National Cancer Center Hospital East) ;
Kawazoe, Akihito (National Cancer Center Hospital East) ;
Conca, Veronica (University of Pisa) ;
Curigliano, Giuseppe (University of Milan) ;
Corti, Francesca (Fondazione IRCCS Istituto Nazionale dei Tumori) ;
Cremolini, Chiara (University of Pisa) ;
Overman, Michael (University of Texas MD Anderson Cancer Center) ;
André, Thierry (Hôpital Saint-Antoine) ;
Pietrantonio, Filippo (Fondazione IRCCS Istituto Nazionale dei Tumori) ;
Universitat Autònoma de Barcelona
Despite unprecedented benefit from immune checkpoint inhibitors (ICIs) in patients with mismatch repair deficient (dMMR)/microsatellite instability high (MSI-H) advanced gastrointestinal cancers, a relevant proportion of patients shows primary resistance or short-term disease control. [...]
2022 - 10.1136/jitc-2021-004001
Journal for immunotherapy of cancer, Vol. 10 (february 2022)
|
|
|
9.
|
|
9 p, 747.7 KB |
The impact of COVID-19 on oncology professionals-one year on : lessons learned from the ESMO Resilience Task Force survey series
/
Lim, K. H. J. (Immunobiology Laboratory, The Francis Crick Institute, London, UK) ;
Murali, K. (Victorian Clinical Genetics Services & Murdoch Children's Research Institute) ;
Thorne, E. (Lancaster University) ;
Punie, K. (University Hospitals Leuven (Bèlgica)) ;
Kamposioras, K. (The Christie NHS Foundation Trust) ;
Oing, C. (University Medical Center Hamburg-Eppendorf) ;
O'Connor, M. (University Hospital Waterford) ;
Elez, Elena (Vall d'Hebron Institut d'Oncologia) ;
Amaral, T. (University Hospital of Tübingen (Alemanya)) ;
Garrido, Pilar (Hospital Universitario Ramón y Cajal (Madrid)) ;
Lambertini, M. (University of Genoa) ;
Devnani, B. (All India Institute of Medical Sciences (Nova Delhi, Índia)) ;
Westphalen, C. B. (LMU Munich and Comprehensive Cancer Center) ;
Morgan, G. (Skåne University Hospital (Suècia)) ;
Haanen, J. B. A. G. (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ;
Hardy, C. (Lancaster University) ;
Banerjee, Susana (The Institute of Cancer Research) ;
Universitat Autònoma de Barcelona
COVID-19 has had a significant impact on the well-being and job performance of oncology professionals globally. The European Society for Medical Oncology (ESMO) Resilience Task Force collaboration set out to investigate and monitor well-being since COVID-19 in relation to work, lifestyle and support factors in oncology professionals 1 year on since the start of the pandemic. [...]
2021 - 10.1016/j.esmoop.2021.100374
ESMO open, Vol. 7 (december 2021)
|
|
|
10.
|
|
19 p, 418.6 KB |
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer : Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
/
Van Cutsem, Eric (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Huijberts, Sanne (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ;
Grothey, Axel (West Cancer Center, Germantown, TN) ;
Yaeger, Rona (Memorial Sloan Kettering Cancer Center) ;
Cuyle, Pieter-Jan (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Elez, Elena (Vall d'Hebron Institut d'Oncologia) ;
Fakih, Marwan (City of Hope National Medical Center (Duarte, Estats Units d'Amèrica)) ;
Montagut, Clara (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Peeters, Marc (University Hospital Antwerp (Bèlgica)) ;
Yoshino, Takayuki (National Cancer Center Hospital East, Kashiwa, Japan) ;
Wasan, Harpreet (Hammersmith Hospital (Londres)) ;
Desai, Jayesh (Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia) ;
Ciardiello, Fortunato (University of Campania "Luigi Vanvitelli" (Nàpols, Itàlia)) ;
Gollerkeri, Ashwin (Array BioPharma Inc) ;
Christy-Bittel, Janna (Array BioPharma Inc) ;
Maharry, Kati (Array BioPharma Inc) ;
Sandor, Victor (Array BioPharma Inc) ;
Schellens, Jan H. M. (Utrecht University) ;
Kopetz, Scott (The University of Texas MD Anderson Cancer Center, Houston, TX) ;
Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Vall d'Hebron Institut de Recerca (VHIR)
To determine the safety and preliminary efficacy of selective combination targeted therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC) in the safety lead-in phase of the open-label, randomized, three-arm, phase III BEACON Colorectal Cancer trial ( identifier: ; European Union Clinical Trials Register identifier: EudraCT2015-005805-35). [...]
2019 - 10.1200/JCO.18.02459
Journal of Clinical Oncology, Vol. 37 (march 2019) , p. 1460-1469
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
